LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Coherus Oncology Inc

Chiusa

SettoreSettore sanitario

1.35

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.34

Massimo

1.42

Metriche Chiave

By Trading Economics

Entrata

354M

298M

Vendite

2.7M

10M

P/E

Media del settore

2.585

35.664

Margine di Profitto

2,903.911

Dipendenti

177

EBITDA

-1.3M

-45M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+217.32% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

59M

159M

Apertura precedente

1.35

Chiusura precedente

1.35

Notizie sul Sentiment di mercato

By Acuity

13%

87%

21 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Coherus Oncology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 set 2025, 17:03 UTC

I principali Market Mover

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 set 2025, 16:49 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

GD Culture Shares Drop After Deal for Pallas Capital

16 set 2025, 16:11 UTC

I principali Market Mover

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 set 2025, 23:40 UTC

Discorsi di Mercato

Nikkei May Decline as Yen Strengthens -- Market Talk

16 set 2025, 23:34 UTC

Discorsi di Mercato

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 set 2025, 23:20 UTC

Discorsi di Mercato

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 set 2025, 21:10 UTC

Acquisizioni, Fusioni, Takeovers

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 set 2025, 20:51 UTC

Discorsi di Mercato

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 set 2025, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

16 set 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

16 set 2025, 20:25 UTC

Utili

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 set 2025, 20:24 UTC

Utili

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 set 2025, 19:19 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 set 2025, 18:52 UTC

Discorsi di Mercato

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 set 2025, 18:44 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

16 set 2025, 18:44 UTC

Discorsi di Mercato

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 set 2025, 18:40 UTC

Acquisizioni, Fusioni, Takeovers

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 set 2025, 18:38 UTC

Discorsi di Mercato

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 set 2025, 18:19 UTC

Discorsi di Mercato

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 set 2025, 18:01 UTC

Discorsi di Mercato

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 set 2025, 17:34 UTC

Discorsi di Mercato

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 set 2025, 16:53 UTC

Utili

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 set 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

16 set 2025, 16:15 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Commodities Roundup: Market Talk

16 set 2025, 16:09 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Energy Roundup: Market Talk

16 set 2025, 16:09 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 set 2025, 15:35 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

16 set 2025, 15:35 UTC

Discorsi di Mercato

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 set 2025, 15:22 UTC

Discorsi di Mercato

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 set 2025, 15:21 UTC

Discorsi di Mercato

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Confronto tra pari

Modifica del prezzo

Coherus Oncology Inc Previsione

Obiettivo di Prezzo

By TipRanks

217.32% in crescita

Previsioni per 12 mesi

Media 4.03 USD  217.32%

Alto 7 USD

Basso 1.1 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Coherus Oncology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

3

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.9209 / 1.05Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

21 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
help-icon Live chat